Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells
Usama A. Fahmy, Shaimaa M. Badr-Eldin, Hibah M. Aldawsari, Nabil A. Alhakamy, Osama A. A. Ahmed, Mohamed F. Radwan, Basma G. Eid, Shaban R. M. Sayed, Gamal A. El Sherbiny, Walaa A. Abualsunun
Abstract
concentrations of 26.07 ± 0.98, 9.166 ± 0.34, and 1.24 ± 0.05 µg/mL, respectively. Furthermore, cell cycle analysis revealed that the nanovesicle was most effective in the G2-M phase, whereas Bax, and Bcl-2 estimates revealed that optimized RLX formula had the highest apoptotic activity among treatments investigated. However, as compared to RLX alone or plain formula alone, the optimized formula demonstrated higher expression of TNFα and Bax while a significant reduction of Bcl-2 and NF-κB expression was observed. mitochondrial membrane potential (MMP) analysis confirmed the apoptosis as well as the anticancer effect of the optimized formula. Thus, the present study results showed an improvement in the anti-PC effects of the RLX with phospholipid conjugated melittin, making it a novel treatment approach against PC.